Qiagen NV (QGEN) - Total Assets

Latest as of December 2025: $6.30 Billion USD

Based on the latest financial reports, Qiagen NV (QGEN) holds total assets worth $6.30 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Qiagen NV for net asset value and shareholders' equity analysis.

Qiagen NV - Total Assets Trend (1995–2025)

This chart illustrates how Qiagen NV's total assets have evolved over time, based on quarterly financial data.

Qiagen NV - Asset Composition Analysis

Current Asset Composition (December 2025)

Qiagen NV's total assets of $6.30 Billion consist of 31.7% current assets and 68.3% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 13.3%
Accounts Receivable $402.61 Million 6.4%
Inventory $301.89 Million 4.8%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $386.43 Million 6.1%
Goodwill $2.70 Billion 42.9%

Asset Composition Trend (1995–2025)

This chart illustrates how Qiagen NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Qiagen NV stock valuation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Qiagen NV's current assets represent 31.7% of total assets in 2025, a decrease from 66.0% in 1995.
  • Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 20.2% in 1995.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 1995.
  • Asset Diversification: The largest asset category is goodwill at 42.9% of total assets.

Qiagen NV Competitors by Total Assets

Key competitors of Qiagen NV based on total assets are shown below.

Company Country Total Assets
Agilent Technologies Inc
NYSE:A
USA $12.73 Billion
Leveljump Healthcare Corp
V:JUMP
Canada CA$21.84 Million
StageZero Life Sciences Ltd
TO:SZLS
Canada CA$580.75K
RHYTHM Biosciences Ltd
AU:RHY
Australia AU$3.10 Million
Sonic Healthcare Ltd
AU:SHL
Australia AU$17.03 Billion
Integral Diagnostics Ltd
AU:IDX
Australia AU$1.43 Billion
Australian Clinical Labs Ltd
AU:ACL
Australia AU$562.50 Million
Healius Ltd
AU:HLS
Australia AU$1.77 Billion

Qiagen NV - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.90 3.61 3.34
Quick Ratio 3.31 3.09 2.70
Cash Ratio 0.00 0.00 0.00
Working Capital $1.48 Billion $1.42 Billion $1.17 Billion

Qiagen NV - Advanced Valuation Insights

This section examines the relationship between Qiagen NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.22
Latest Market Cap to Assets Ratio 1.13
Asset Growth Rate (YoY) 10.7%
Total Assets $6.30 Billion
Market Capitalization $7.10 Billion USD

Valuation Analysis

Above Book Valuation: The market values Qiagen NV's assets above their book value (1.13x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: Qiagen NV's assets grew by 10.7% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Qiagen NV (1995–2025)

The table below shows the annual total assets of Qiagen NV from 1995 to 2025.

Year Total Assets Change
2025-12-31 $6.30 Billion +10.66%
2024-12-31 $5.69 Billion -6.96%
2023-12-31 $6.12 Billion -2.74%
2022-12-31 $6.29 Billion +2.29%
2021-12-31 $6.15 Billion +4.72%
2020-12-31 $5.87 Billion +12.11%
2019-12-31 $5.24 Billion -8.92%
2018-12-31 $5.75 Billion +14.09%
2017-12-31 $5.04 Billion +16.95%
2016-12-31 $4.31 Billion +2.83%
2015-12-31 $4.19 Billion -5.94%
2014-12-31 $4.45 Billion +8.95%
2013-12-31 $4.09 Billion -0.91%
2012-12-31 $4.13 Billion +9.84%
2011-12-31 $3.76 Billion -4.03%
2010-12-31 $3.91 Billion +3.10%
2009-12-31 $3.80 Billion +31.58%
2008-12-31 $2.89 Billion +3.97%
2007-12-31 $2.78 Billion +128.97%
2006-12-31 $1.21 Billion +58.37%
2005-12-31 $765.30 Million +7.09%
2004-12-31 $714.60 Million +29.47%
2003-12-31 $551.93 Million +21.43%
2002-12-31 $454.51 Million +27.33%
2001-12-31 $356.97 Million +55.03%
2000-12-31 $230.26 Million +55.46%
1999-12-31 $148.12 Million +38.82%
1998-12-31 $106.70 Million +35.23%
1997-12-31 $78.90 Million +19.18%
1996-12-31 $66.20 Million +152.67%
1995-12-31 $26.20 Million --

About Qiagen NV

NYSE:QGEN USA Diagnostics & Research
Market Cap
$7.10 Billion
Market Cap Rank
#2851 Global
#987 in USA
Share Price
$34.44
Change (1 day)
+1.29%
52-Week Range
$33.61 - $55.66
All Time High
$56.87
About

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more